Cobenfy: A New Antipsychotic
The Carlat Psychiatry Podcast
00:00
Intro
This chapter explores the FDA's recent approval of Cabenphi, an antipsychotic with a unique mechanism that moves beyond traditional dopamine antagonists. It also recounts personal experiences during a tumultuous conference impacted by Hurricane Helene, while delving into the scientific background of its key component, xanomaline.
Transcript
Play full episode
